Xiaofang Pharmaceutical (603207.SH) released its half-year financial results, with a net profit attributable to shareholders of 1.21 billion yuan, a year-on-year increase of 1.69%.

Wisdom Financial APP news, Xiaofang Pharmaceuticals (603207.SH) disclosed its interim report for the first half of 2025. During the reporting period, the company achieved a revenue of 270 million yuan, a year-on-year increase of 3.06%; net profit attributable to shareholders was 121 million yuan, a year-on-year increase of 1.69%; net profit after deducting non-recurring items was 121 million yuan, a year-on-year increase of 2.04%; basic earnings per share were 0.75 yuan. The company plans to distribute a cash dividend of 7.00 yuan (tax included) per 10 shares to all shareholders.